In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%. In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's Natco Pharma to sell generic drug Nexavar,...
More »SEARCH RESULT
A major milestone in polio eradication by T Jacob John
While one year has passed without polio caused by natural poliovirus, we can claim complete eradication only after we ensure the absence of wild and vaccine polioviruses in the population. Today, India passes one whole year without polio caused by natural (wild) poliovirus — a major milestone towards polio eradication. This spells relief from an agonising decade of wild polioviruses refusing to surrender. Many experts believed that India posed the greatest...
More »FDI if retailers procure 30% stuff from small industry by Surajeet Das Gupta & Nayanima Basu
Indian suppliers must be units with investment up to Rs 1.25 cr, says draft before cabinet. Multinational retailers such as Walmart, Tesco and Carrefour looking to open stores in the country may have to source almost a third of their merchandise from small Indian manufacturers as the government tries to make the opening of multi-brand retail to foreign players more politically palatable. The draft cabinet note for permitting 51 per cent foreign...
More »Medicines: For Saving Life or For Superprofits? by Bharat Dogra
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage. It may be pointed out here that as early as...
More »"BRICS Can Ensure Affordable Drugs" by Ranjit Devraj
While ‘data exclusivity’ clauses will not feature in the India-European Union free trade agreement (FTA), the threat posed by the impending deal to the world’s supply of cheap generic drugs is far from over. India’s commerce and industry minister Anand Sharma assured Michel Sidibe, chief of the United Nations joint programme on HIV and AIDS (UNAIDS) at a meeting this week that India would reject attempts by pharmaceutical giants to include...
More »